X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1182) 1182
index medicus (1051) 1051
aurora kinases (752) 752
protein-serine-threonine kinases - antagonists & inhibitors (679) 679
animals (626) 626
protein kinase inhibitors - pharmacology (495) 495
cell line, tumor (471) 471
oncology (456) 456
cancer (427) 427
protein-serine-threonine kinases - metabolism (427) 427
phosphorylation (365) 365
mice (347) 347
cell biology (322) 322
mitosis (300) 300
antineoplastic agents - pharmacology (297) 297
female (286) 286
apoptosis (264) 264
aurora kinase b (255) 255
cell proliferation - drug effects (236) 236
biochemistry & molecular biology (235) 235
small-molecule inhibitor (229) 229
apoptosis - drug effects (223) 223
aurora kinase a - antagonists & inhibitors (220) 220
kinases (217) 217
aurora kinase (212) 212
cell cycle (208) 208
article (197) 197
protein-serine-threonine kinases - genetics (195) 195
protein kinase inhibitors - chemistry (182) 182
expression (178) 178
male (178) 178
research (176) 176
aurora kinase a (174) 174
chemistry, medicinal (171) 171
xenograft model antitumor assays (165) 165
hela cells (164) 164
pyrimidines - pharmacology (164) 164
pharmacology & pharmacy (160) 160
in-vivo (157) 157
protein kinase inhibitors - therapeutic use (157) 157
proteins (151) 151
aurora kinase a - metabolism (143) 143
neoplasms - drug therapy (142) 142
analysis (140) 140
a kinase (137) 137
phosphotransferases (135) 135
activation (134) 134
structure-activity relationship (132) 132
antineoplastic agents - therapeutic use (130) 130
cell cycle proteins - metabolism (130) 130
mitosis - drug effects (128) 128
dose-response relationship, drug (124) 124
aurora kinase b - antagonists & inhibitors (119) 119
mice, nude (114) 114
models, molecular (114) 114
cells (113) 113
overexpression (112) 112
quinazolines - pharmacology (112) 112
cell cycle - drug effects (109) 109
rna interference (108) 108
tumors (108) 108
enzyme inhibitors - pharmacology (106) 106
histones - metabolism (106) 106
kinase (105) 105
piperazines - pharmacology (105) 105
aurora-a (104) 104
care and treatment (100) 100
signal transduction (100) 100
health aspects (99) 99
mutation (99) 99
chromosome segregation (98) 98
antineoplastic agents - chemistry (97) 97
aurora-b (97) 97
cell survival - drug effects (97) 97
cell cycle proteins - antagonists & inhibitors (96) 96
inhibitors (95) 95
potent (95) 95
protein (95) 95
growth (94) 94
genetic aspects (93) 93
protein binding (93) 93
cell proliferation (91) 91
b kinase (87) 87
molecular structure (87) 87
gene expression (85) 85
phosphorylation - drug effects (85) 85
drug design (84) 84
aurora kinases - antagonists & inhibitors (83) 83
signal transduction - drug effects (83) 83
cell cycle proteins - genetics (82) 82
cell division (82) 82
cytokinesis (81) 81
spindle assembly checkpoint (81) 81
aurora kinase b - metabolism (80) 80
cell line (80) 80
chromosomes (80) 80
hematology (80) 80
checkpoint (79) 79
discovery (79) 79
histone h3 (79) 79
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Cancer, ISSN 1474-175X, 01/2017, Volume 17, Issue 2, pp. 93 - 115
Journal Article
Oncology Reports, ISSN 1021-335X, 06/2016, Volume 35, Issue 6, pp. 3696 - 3704
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 2015, Volume 45, Issue 12, pp. 1097 - 1102
Cellular proliferation is tightly controlled by several cell-cycle checkpoint proteins. In cancer, the genes encoding these proteins are often disrupted and... 
Cyclin-dependent kinase | Cell-cycle check-point | Polo-like kinase | Aurora kinase | Palbociclib | CDK4/6 inhibitor | cell-cycle check-point | aurora kinase | DEPENDENT KINASE INHIBITOR | CANCER | I DOSE-ESCALATION | BREAST | TRIAL | WEE1 KINASE | ONCOLOGY | polo-like kinase | VOLASERTIB BI 6727 | cyclin-dependent kinase | palbociclib | PHASE-I | INVESTIGATIONAL AURORA | Triazoles - administration & dosage | Estradiol - analogs & derivatives | Cell Proliferation | Estrogen Receptor Antagonists - administration & dosage | Humans | Receptors, Estrogen - analysis | Aurora Kinase A - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Nitriles - administration & dosage | Breast Neoplasms - chemistry | Molecular Targeted Therapy - trends | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Female | Cyclin-Dependent Kinases - antagonists & inhibitors | Molecular Targeted Therapy - methods | Aromatase Inhibitors - administration & dosage | Biomarkers, Tumor - analysis | Estradiol - administration & dosage | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Protein Kinase Inhibitors - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Breast Neoplasms - mortality | Protein Kinase Inhibitors - pharmacology | Receptor, ErbB-2 - analysis | Neoplasm Staging | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Cancer Research, ISSN 0008-5472, 10/2013, Volume 73, Issue 20, pp. 6310 - 6322
Journal Article
Journal Article
Journal of Cell Biology, ISSN 0021-9525, 11/2017, Volume 216, Issue 11, pp. 3571 - 3590
Establishing the bipolar spindle in mammalian oocytes after their prolonged arrest is crucial for meiotic fidelity and subsequent development. In contrast to... 
XENOPUS EGG EXTRACTS | CENTROSOME BIOGENESIS | EARLY MOUSE DEVELOPMENT | MITOTIC SPINDLE | MEIOSIS-I | MEIOTIC MATURATION | SELF-ORGANIZATION | MICROTUBULE DYNAMICS | GAMMA-TUBULIN | CENTRIOLE DUPLICATION | CELL BIOLOGY
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2015, Volume 58, Issue 1, pp. 362 - 375
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3756 - 3768
Purpose: Aurora kinase A (AURKA) is overexpressed in several cancer types, making it an attractive druggable target in clinical trials. In this study, we... 
MAMMALIAN TARGET | ONCOLOGY | GASTRIC-CANCER | SIGNALING PATHWAY | INDUCED APOPTOSIS | PHOSPHORYLATION | GROWTH | TRANSLATION | PROMOTES | INVESTIGATIONAL AURORA | ESOPHAGEAL CANCERS | Cell Survival - drug effects | Adenocarcinoma - pathology | Gastrointestinal Neoplasms - genetics | Apoptosis - drug effects | Gastrointestinal Neoplasms - drug therapy | Humans | Everolimus - administration & dosage | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Adenocarcinoma - drug therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Xenograft Model Antitumor Assays | Gastrointestinal Neoplasms - pathology | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Everolimus - adverse effects | Adenocarcinoma - genetics | Mice | Proto-Oncogene Proteins c-myc - genetics | Gene Expression Regulation, Neoplastic - drug effects | Eukaryotic Initiation Factor-4E - genetics | Aurora Kinase A - genetics | Drug Resistance, Neoplasm - drug effects | TOR protein | Cell culture | Phosphorylation | Animal models | Phosphoprotein phosphatase | c-Myc protein | Clinical trials | AKT protein | Activation | Aurora kinase | Myc protein | Kinases | Subgroups | Proteins | Rodents | Xenografts | Medical research | Translation | Cell survival | Extracellular signal-regulated kinase | Pharmacology | Inhibitors | Experimental design | Protein phosphatase | Initiation factor eIF-4E | Cancer | Tumors
Journal Article
Journal Article
Cell Cycle, ISSN 1538-4101, 07/2014, Volume 13, Issue 14, pp. 2237 - 2247
Polo-like kinases (PLKs) and Aurora kinases (AKs) act as key cell cycle regulators in healthy human cells. In cancer, these protein kinases are often... 
Aurora kinases | MEK/ERK/mTORC1 | cell cycle | PI3K/Akt/mTORC2 | apoptosis | polo-like kinases | T-ALL | caspases | Polo-like kinases | Cell cycle | Caspases | Apoptosis | MAMMALIAN TARGET | RAPAMYCIN | ACUTE MYELOID-LEUKEMIA | ONCOGENIC TRANSFORMATION | CYTOTOXIC ACTIVITY | CANCER | CELL BIOLOGY | 1 PLK1 | PATHWAY | RESISTANCE | INHIBITOR BI 2536 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Aurora Kinase B - metabolism | Apoptosis - drug effects | Coculture Techniques | Humans | Aza Compounds - pharmacology | Aurora Kinase A - antagonists & inhibitors | Molecular Targeted Therapy | Aurora Kinase A - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | G2 Phase Cell Cycle Checkpoints - drug effects | Drug Design | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Tumor Cells, Cultured | Aurora Kinase B - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Cell Survival - drug effects | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Proto-Oncogene Proteins - antagonists & inhibitors | Jurkat Cells | Cell Cycle Proteins - metabolism | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Drug Synergism | Animals | Signal Transduction - drug effects | Cyclohexanecarboxylic Acids - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Report | Akt | MEK | PI3K | mTORC2 | mTORC1 | ERK
Journal Article